International Journal of Hepatology / 2012 / Article / Tab 2

Review Article

Liver Transplantation and Hepatitis C

Table 2

Studies of antiviral treatment with pegylated interferon alpha and ribavirin for established recurrent hepatitis C after liver transplantation.

AuthorYearIncluded patients ( )Genotype 1 (%)FCHPEG-INF alpha (dose)RBV dose (mg/day)Time since LTTreatment duration (months)Growth factorSVR,
(%)
Discontinuation (%)Dose reductions (%)

Rodriguez-Luna et al. [199]20041963NA2b: 0.5–1.5 μg/kg per week ( )400 then escalated to 800–10004.2 (1–16.2)12Yes5 (26)7 (38)NA
Neff et al. [200]20045798NA2b: 1.5 μg/kg per week ( )400–60023.5 (1.6–84.7)12Yes8 (14)18 (32)INF 38 (67), RBV 22 (39)
Ross et al. [201]2004166922b: 1.5 μg/kg per week ( )800–12009.512Yes0 (0)8 (50)INF 12 (75), RBV 13 (81)
Dumortier et al. [202]2004208002b: 0.5–1 μg/kg per week ( )40028 (3–103)12No9 (45)4 (20)INF 13 (65), RBV 6 (30)
Babatin et al. [203]2005134602b: 0.9 μg/kg per week ( )60024 (6–73)12Yes4 (31)7 (54)9 (72)
Toniutto et al. [204]20051210002b: 0.5 μg/kg per week ( )600–80014 (0.6–60.8)12No1 (8)7 (58)11 (92)
Castells et al. [205]2005241002b: 1.5 μg/kg per week ( )6003.8 ± 2.212Yes8 (35)3 (13)INF 6 (25), RBV 14 (58)
Biselli et al. [206]2006208002b: 1 μg/kg per week ( )60056.5 (13–157)12Yes9 (45)1 (5)RBV 7 (35)
Berenguer et al. [207]20063689NA2b: 1.5 μg/kg per week ( ),
2a: 180 μg/week ( )
600–120016.6 (2.7–132.6)12Yes18 (50)17 (47)19 (53)
Oton et al. [208]2006559102b: 1.5 μg/kg per week ( ),
2a: 180 μg/week ( )
800–120063.3 ± 45.5G1/4: 12, G2/3: 6Yes24 (44)16 (29)INF 17 (31), RBV 17 (31)
Mukherjee and Lyden [209]20063275NA2a: 180 μg/week ( )800 then escalated to 1000–120016 (2–70)G1/4: 12, G2/3: 6Yes11 (34)5 (16)NA
Mukherjee and Lyden [210]20063979NA2b: 1.5 μg/kg per week ( )80020 (2–168)G1/4: 12, G2/3: 6No13 (33)17 (44)NA
Fernández et al. [211]20064794102b: 1.5 μg/kg per week ( )600–80032 ± 2512Yes11 (23)10 (21)RBV 15 (32)
Neumann et al. [212]2006258002b: 1 μg/kg per week ( )60038 (2–108)12Yes9 (36)1 (4)INF 15 (52), RBV 9 (36)
Neumann et al. [212] 2006618702b: 1 μg/kg per week ( )600–80025 (3–131)G1/4: 12, G2/3: 6No17 (28)9 (15)48 (79)
Angelico et al. [214]2007428102a: 180 μg/week ( )200 then escalated to 1200 until tolerated48 ± 2912No7 (33)7 (33)INF 8 (38), RBV 21 (100)
Carrión et al. [215]2007819342b: 1.5 μg/kg per week ( )400–1200 adjusted for renal function14.5 (2–38)12Yes18 (33)21 (39)INF 13 (24), RBV 36 (67)
Sharma et al. [216]2007357712b: 1.5 μg/kg per week,
2a: 180 μg/week, (no of patients not stated)
80016 (1.5–129)12Yes13 (37)15 (43)NA
Zimmermann et al. [217]2007268802a: 90 μg/week for 4 weeks then escalated to 135–180 μg/week ( )600 then escalated to 800–12009.4 ± 3.612Yes5 (19)3 (12)17 (65)
Dinges et al. [218] 20091968NA2a: 180 μg/week ( )10 mg/kg/day23 (6–162)12Yes9 (47)5 (26)INF 8 (50), RBV 7 (37)
Lodato et al. [219]20085310002b: 1.0 μg/kg per week ( )8–10 mg/kg/day14 (3–151)12Yes14 (26)24 (45)INF 3 (6), RBV 21 (40)
Roche et al. [27]2008133 (29: INF)75NA2b: 0.6–1.5 μg/kg per week ( ), 2a: 90–180 μg/week ( )1.8–16.9 mg/kg/day86 (5–231)12Yes58 (44)41 (38)INF 41 (38), RBV 80 (60)
Hanouneh et al. [220]2008537902b: 1.5 μg/kg per week,
2a: 180 μg/week, (no. of patients not stated)
1000–120015 (7–39)12Yes19 (35)14 (26)31 (58)
Berenguer et al. [28]200910786112b: 1.5 μg/kg per week ( ),
2a: 180 μg/week ( )
600–120021 (2–133)12Yes39 (37)INF 37 (35), RBV 43 (40)
Selzner et al. [26]2009172 (36: INF)6862b: 1.5 μg/kg per week,
2a: 180 μg/week, (no. of patients not stated)
800–100019 (1–149)12Yes86 (50)29 (17)80 (47%)
Schmidt et al. [221]20108388NA2b: 1.0 μg/kg per week ( ),
2a: 180 μg/week ( )
400–100041 (0.6–144)12Yes31 (26)24 (29)49 (51)
Jain et al. [222]20106093NA2b: 1–1.5 μg/kg per week ( ),
2a: 180 μg/week ( )
80029 ± 2812Yes21 (35)24 (40)INF 21 (35), RBV 16 (27)
Al-Hamoudi et al. [223]2011250 (All genotype 4)NA2a: 180 μg/week ( )400–120014 (1–72)12Yes14 (56)1 (4)INF 0 (0), RBV 7 (28)

Abbreviations: FCH: fibrosing cholestatic hepatitis; INF: interferon; LT: liver transplantation; NA: not available; PEG-INF: pegylated-interferon; RBV: ribavirin; SVR: sustained viral response.